Skip to main content

Advertisement

Log in

High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series

  • Short Communication
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

The objective of this study was to evaluate the clinical benefit and the side effects of high dosages of betahistine dihydrochloride (288–480 mg/day) in patients with severe Menière’s disease (MD). In this case series 11 patients with MD who had not responded sufficiently to a dosage of 144 mg/day of betahistine dihydrochloride were treated on an individual basis with daily dosages between 288 and 480 mg of betahistine dihydrochloride. The number of attacks per month and the side effects were monitored. Non-parametric tests were used for statistical analysis. As a result, the frequency and the severity of vertigo were significantly reduced in all patients. The side effects were mild, self-limiting, and did not require any change in the treatment strategy. Despite the considerable limitations of an observational study—in particular in MD—high dosages of betahistine dihydrochloride between 288 and 480 mg/day seem to be effective in patients who do not sufficiently respond to lower dosages. Moreover, such dosages are well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg. (1995) 113(3):181–185

  2. Merchant SN, Adams JC, Nadol JB Jr (2005) Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol 26(1):74–81

    Article  PubMed  Google Scholar 

  3. Dieterich M, Brandt T (1999) Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 246(10):883–892

    Article  PubMed  CAS  Google Scholar 

  4. Guilemany JM, Martinez P, Prades E, Sanudo I, De Espana R, Cuchi A (2004) Clinical and epidemiological study of vertigo at an outpatient clinic. Acta Otolaryngol 124(1):49–52

    Article  PubMed  CAS  Google Scholar 

  5. Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 56(4):436–441

    PubMed  CAS  Google Scholar 

  6. van Cruijsen N, Jaspers JP, van de Wiel HB, Wit HP, Albers FW (2006) Psychological assessment of patients with Meniere’s disease. Int J Audiol 45(9):496–502

    Article  PubMed  Google Scholar 

  7. Eckhardt-Henn A, Best C, Bense S, Breuer P, Diener G, Tschan R et al (2008) Psychiatric comorbidity in different organic vertigo syndromes. J Neurol 255(3):420–428

    Article  PubMed  Google Scholar 

  8. Sajjadi H, Paparella MM (2008) Meniere’s disease. Lancet 372(9636):406–414

    Article  PubMed  Google Scholar 

  9. Strupp M, Hupert D, Frenzel C, Wagner J, Hahn A, Jahn K et al (2008) Long-term prophylactic treatment of attacks of vertigo in Meniere’s disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol 128(5):520–524

    Article  PubMed  CAS  Google Scholar 

  10. Jeck-Thole S, Wagner W (2006) Betahistine: a retrospective synopsis of safety data. Drug Saf 29(11):1049–1059

    Article  PubMed  CAS  Google Scholar 

  11. James AL, Burton MJ (2001) Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev (1): CD001873

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Franziska Lezius.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lezius, F., Adrion, C., Mansmann, U. et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series. Eur Arch Otorhinolaryngol 268, 1237–1240 (2011). https://doi.org/10.1007/s00405-011-1647-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-011-1647-2

Keywords

Navigation